Biotech startup demonstrates rapid AI design of full-length human antibodies that inhibit or activate GPCRs, with key properties required for therapeutic development

Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, today announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027891477/en/

Pythia's AI technology platform can design antibodies against traditionally challenging targets such as multi-pass membrane proteins.

Pythia’s technology is built to create antibodies against targets that have challenged conventional discovery, including multi-pass membrane proteins such as G protein-coupled receptors (GPCRs). Generating antibodies that activate these receptors has been a longstanding goal in antibody discovery. Pythia-1 reasons jointly over amino acid sequence, three-dimensional atomic structure and explicit design specifications. The platform provides control over where an antibody binds, the conformational state of the target it recognizes, and key antibody attributes. This allows functional objectives and development requirements to shape designs from the outset.

Pythia’s proof-of-concept study, published this week in bioRxiv, evaluated full-length human IgGs designed from scratch across 22 therapeutic targets. Following a single computational design round, experimental screening of around 48 candidates per target identified antibodies with single-digit nanomolar affinities for soluble proteins and single-digit nanomolar cell-binding EC50 values for GPCRs. Cell-based functional assays demonstrated both GPCR agonism and antagonism, including single-digit nanomolar inhibitory potency against multiple GPCRs. Characterized antibodies also exhibited biophysical properties that compared favorably with clinical-stage therapeutic antibodies.

The study and its compelling results were made public this week in a bioRxiv preprint entitled “Design of Full-Length Agonist and Antagonist Antibodies for Hard Targets”. Pythia is also sharing complete sequences of all lead antibodies presented in the study at pythialabs.com, to support independent validation and further research.

By extending antibody discovery into areas of biology that conventional methods have struggled to access, Pythia’s technology creates new opportunities to develop transformative medicines previously beyond reach.

About Pythia Labs

Pythia Labs builds frontier AI models for therapeutic discovery. The company is beginning with next-generation antibodies for hard-to-drug targets. Its scientists and engineers combine expertise in generative modeling, computational biology and drug discovery to open new possibilities for creating better medicines.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261027891477/en/

Media Contact:
Josh Laniado, Scientific Founder
contact@pythialabs.com

Logo

Images

Tags

More Like This

genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure

Proteintech Launches “Able” AI – A First-of-Its-Kind Tool to Accelerate Scientific Discovery

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase Model Leading a New Trend in Antibody Drug Development

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody

Proteintech Unveils Next-Gen 3D Epitope Mapping to Accelerate Life Science Research